Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients
James B Rawson, Michael Manno, Miralem Mrkonjic, Darshana Daftary, Elizabeth Dicks, Daniel D Buchanan, H Banfield Younghusband, Patrick S Parfrey, Joanne P Young, Aaron Pollett, Roger C Green, Steven Gallinger, John R McLaughlin, Julia A Knight, Bharati Bapat
Carcinogenesis | OXFORD UNIV PRESS | Published : 2011
Awarded by Canadian Institutes of Health Research
Awarded by National Cancer Institute (NCI) under Request For Applications
Awarded by Colon Cancer Familial Registry
This work was supported by a Team Grant from the Canadian Institutes of Health Research (CTP-79845) awarded to J.R.M., B.B., J.A.K., S.S.G., R.C.G. and P.S.P.; by the National Cancer Institute (NCI) under Request For Applications (CA-95-011) and through cooperative agreements within the Colon Cancer Familial Registry (U01 CA074783) awarded to the Ontario Registry for Studies of Familial Colorectal Cancer (Principle Investigator: S.S.G.). The content of this article does not necessarily reflect the views or policies of the NCI or any of the collaborating centers in the Cancer Family Registry (CFR) nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government or CFR. J.B.R. was supported by graduate studentships from the Team in Interdisciplinary Research on Colorectal Cancer funded by the Canadian Institutes of Health Research and by graduate studentships from the Department of Laboratory Medicine and Pathobiology at the University of Toronto.